• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Drug Approvals Don't Always Translate Into Stock Gains: 3 Biotech Examples

Winning FDA approval isn't always a win.
By BRET JENSEN
Sep 23, 2017 | 02:00 PM EDT
Stocks quotes in this article: NEOS, ADMS, SGYP

I tend to get a slew of questions every week regarding the strange price movements, both immediate and near term, that small biotech and biopharma stocks can have after U.S. Food and Drug Administration (FDA) drug approvals. There are still quite a few investors in the market who believe FDA approval means their stock should continue to ascend. Unfortunately, like almost everything else is this high-beta and at times maddening space, it isn't quote so straightforward.

Here are three things that are likely to guide any small or midcap equity in this space directly after approval and in the months after that as well.

  1. What did the stock do in the weeks leading up to the approval date?
  2. What were certainty, impact and clarity of the FDA decision?
  3. How challenging or easy is the rollout of the approved compound likely to be?

Usually a stock will get the most pop if there is little run-up in price into the decision date, the drug will have meaningful impact on the company's business prospects and there is some or considerable uncertainty whether the drug candidate will be approved. When those traits are not there, you easily can get some "buy the rumor, sell the news" trading action even when the FDA gives the green light. This recently happened to Neos Therapeutics Inc. (NEOS) , which is down about 10% since its compound NT-201 was approved on Friday. Of course, the stock ran up 30% in the month prior to the FDA action, this is third drug approval this small-cap concern has garnered in the past year and it probably has the least impact of the three compounds approved over that time span. Therefore, the slight selloff after approval.

Going the other way is the stock of Adamas Pharmaceuticals Inc. (ADMS) , which is up 50% since its drug Gocovri was approved a few weeks ago. The stock did not run up into its approval date, primarily because there were considerable concerns that the FDA would not give it the go-ahead. When a thumbs up was given, it was off to the races as Gocovri, which is likely to be Adamas' primary growth engine in the years ahead.

Then there is the difficulty of the initial rollout of the drug once approved. The easiest drugs to roll out are those for rare or ultra-rare afflictions with no current competitors on the market. Most of the potential patients that have these types of diseases are known, are seen by a relatively few number of specialists, and can be served by a small sales force. Once reimbursement coverage is achieved, sales can ramp up quickly with a relatively limited amount of investment.

The hardest drugs to garner market share are in spaces with alternatives and those aimed at the mass market. This requires significant investment or a distribution deal with a larger drug giant as well as a large sales force and numerous sales aids and education efforts. These are the challenges Synergy Pharmaceuticals Inc. (SGYP) has encountered in rolling out Trulance, which was approved for the treatment of chronic idiopathic constipation in January.

While Synergy's drug is superior to the market-leading drug in the space in a couple important ways, it has entered a huge market with more than 30 million potential customers who are served by tens of thousands of gastrointestinal specialists. The stock has been cut in half since approval. Trulance sales should be running at a $50 million annual rate by the end of the year. However, it has been a tough slog and the company recently did a $300 million debt deal to support long-term marketing of this drug. Investors have had to exhibit more patience that they would have thought on this name nine months ago.

So, as with most questions in this sector of the market, the answer to this sort of inquiry is usually "it depends."

This commentary originally appeared on Real Money Pro on Sept. 20. Click here to learn about this dynamic market information service for active traders.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long ADMS, NEOS and SGYP.

TAGS: Investing | U.S. Equity | Healthcare | How-to

More from Healthcare

Boston Scientific Could Be Wicked Good in This Kind of Market

Brad Ginesin
May 24, 2022 2:13 PM EDT

Here's why this healthcare stock is a potential port in the storm for investors.

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login